Detailed information for compound 251902

Basic information

Technical information
  • TDR Targets ID: 251902
  • Name: (Z)-4-methoxy-1-[4-[(2-methylimidazo[4,5-c]py ridin-1-yl)methyl]piperidin-1-yl]-3-phenylbut -2-en-1-one
  • MW: 404.505 | Formula: C24H28N4O2
  • H donors: 0 H acceptors: 3 LogP: 2.94 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: COC/C(=C\C(=O)N1CCC(CC1)Cn1c(C)nc2c1ccnc2)/c1ccccc1
  • InChi: 1S/C24H28N4O2/c1-18-26-22-15-25-11-8-23(22)28(18)16-19-9-12-27(13-10-19)24(29)14-21(17-30-2)20-6-4-3-5-7-20/h3-8,11,14-15,19H,9-10,12-13,16-17H2,1-2H3/b21-14+
  • InChiKey: JNGHAFCRPYOSHO-KGENOOAVSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (Z)-4-methoxy-1-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]-1-piperidyl]-3-phenyl-but-2-en-1-one
  • (Z)-4-methoxy-1-[4-[(2-methyl-1-imidazo[4,5-c]pyridinyl)methyl]-1-piperidinyl]-3-phenyl-2-buten-1-one
  • (Z)-4-methoxy-1-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidin-1-yl]-3-phenyl-but-2-en-1-one
  • (Z)-4-methoxy-1-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]piperidino]-3-phenyl-but-2-en-1-one
  • (Z)-4-methoxy-1-[4-[(2-methyl-1-imidazo[4,5-c]pyridinyl)methyl]-1-piperidinyl]-3-phenylbut-2-en-1-one

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus multilocularis dihydrofolate reductase 0.0567 0.2728 1
Schistosoma mansoni dihydrofolate reductase 0.0567 0.2728 1
Loa Loa (eye worm) dihydrofolate reductase 0.0567 0.2728 1
Echinococcus granulosus dihydrofolate reductase 0.0567 0.2728 1
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.0567 0.2728 1
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.0567 0.2728 1
Chlamydia trachomatis dihydrofolate reductase 0.0567 0.2728 0.5
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 0.0811 1 0.5
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 0.0811 1 0.5
Brugia malayi Dihydrofolate reductase 0.0567 0.2728 1
Brugia malayi dihydrofolate reductase family protein 0.0567 0.2728 1
Onchocerca volvulus 0.0475 0 0.5
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.0811 1 0.5
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.0811 1 0.5
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.0567 0.2728 1
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.0811 1 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (functional) = 0.018 uM Concentration required to inhibit PAF-induced maximum platelet aggregation in rabbit platelet-rich plasma ChEMBL. 8558517
ID50 (functional) = 0.0079 mg kg-1 Dosage required to inhibit PAF-induced mortality in mice by 50% through intravenous route ChEMBL. 8558517
ID50 (functional) = 0.0079 mg kg-1 Dosage required to inhibit PAF-induced mortality in mice by 50% through intravenous route ChEMBL. 8558517
ID50 (functional) = 0.022 mg kg-1 Dose required to reduce the lowering of the arterial blood pressure caused by PAF by 50% after intravenous administration in rats ChEMBL. 8558517
ID50 (functional) > 1 mg kg-1 Dosage required to inhibit PAF-induced mortality in mice by 50% through oral administration ChEMBL. 8558517
ID50 (functional) > 1 mg kg-1 Dosage required to inhibit PAF-induced mortality in mice by 50% through oral administration ChEMBL. 8558517

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.